Bristol Myers Squibb (CELG-RI) Net Margin (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Net Margin for 18 consecutive years, with 25.56% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Margin rose 1486.0% year-over-year to 25.56% in Q2 2026; TTM through Jun 2026 was 18.86%, a 824.0% increase from a year earlier, with the FY2025 full-year figure at 14.64%, up 3314.0% from the prior year.
• Net Margin was 25.56% for Q2 2026 at Bristol Myers Squibb, up from 23.32% in the prior quarter.
• Over five years, Net Margin peaked at 25.56% in Q2 2026 and troughed at 100.36% in Q1 2024.
• A 5-year average of 8.84% and a median of 14.84% in 2022 frame the typical range for Net Margin.
• Across the five-year window, Net Margin sank 12036 bps in 2024 and jumped 12234 bps in 2025, its largest moves.
• Over 5 years, Net Margin stood at 17.75% in 2022, then decreased by 14 bps to 15.35% in 2023, then plunged by 96 bps to 0.62% in 2024, then surged by 1311 bps to 8.69% in 2025, then jumped by 194 bps to 25.56% in 2026.
• The last three Net Margin figures came in at 25.56% (Q2 2026), 23.32% (Q1 2026), and 8.69% (Q4 2025), per Business Quant data.